Boston's Watchman edges closer to US approval with feasibility study success
This article was originally published in Clinica
Executive Summary
Boston Scientific's Watchman device has been shown to reduce the risk of ischaemic stroke by 75% in a feasibility study, raising hopes that it will eventually be approved in the US. However, the FDA green light is still some time away – Boston is currently enrolling patients in a Phase III study to support approval. The company is anticipating FDA approval and US launch in 2013.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.